8-K filed Nov 5, 2026 at 07:00 ET
Karyopharm Therapeutics received a delisting notice from Nasdaq following its Chapter 11 bankruptcy filing on November 2, 2026. Nasdaq determined to delist the company's common stock based on public interest concerns, residual equity concerns, and compliance issues. The company will not appeal, trading will be suspended on Nasdaq at the open on November 11, 2026, and the stock is expected to move to OTC under symbol KPTIQ. The company's prepackaged Chapter 11 plan provides that holders of common stock and preferred stock will receive no distribution, implying a complete loss of equity value.